Low molecular weight heparin (LMWH) therapy guided by low placental growth factor (PlGF) in a diabetes-prevalent population: preliminary retrospective cohort

Pregnancy Hypertension 2026 Open access

Read full text
Authors: Ernesto A. Figueiro-Filho, Genevieve M. Dietrich, Alysa A. Poulin, Adrielle P. Souza Lira, Eman Ramadan, Adewumi Adanlawo, Pedro H.G. Guedes, Ana Paula Mendes-Silva, Joshua D. Buse
DOI: 10.1016/j.preghy.2026.101423
Cited by: 1
References: 37

Abstract

OBJECTIVES: Low placental growth factor (PlGF < 5th centile) is predictive of preeclampsia, fetal growth restriction (FGR) and preterm birth. In our region, diabetes during pregnancyincreasesthe risk of placental dysfunction. Preclinical and clinical studies suggest that low-molecular-weight heparin (LMWH) can increase PlGF levels. We assessed whether prophylactic LMWH was associated with improved outcomes in pregnancies with low PlGF within a diabetes-prevalent population. STUDY DESIGN: Retrospective cohort of 471 singleton pregnancies tested for PlGF between Dec 2021-Jan 2025. PlGF was classified as normal (>10th centile) or low (

Fields of Study & Subjects

Pregnancy and preeclampsia studies Blood Coagulation and Thrombosis Mechanisms Proteoglycans and glycosaminoglycans research

Publication details

Journal / source
Pregnancy Hypertension
Publisher
Elsevier BV
Volume
43
Pages
101423–101423
Publication date
3 February 2026
Language
EN